IP Library › Granted Patent US 9,944,649

Granted Patent B2

US 9,944,649 · App. 15/307,510 · Granted Apr 17, 2018

Compounds and compositions as toll-like receptor 7 agonists

Inventors: Alex Cortez (San Diego, CA); Timothy Hoffman (San Diego, CA); Yongkai Li (Del Mar, CA); Tom Yao-Hsiang Wu (San Diego, CA); Xiaoyue Zhang (San Diego, CA)

Assignee: Novartis Ag

C07D487/04

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 9,944,649
App. No.: 15/307,510
Granted: Apr 17, 2018
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The invention provides a compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat diseases or disorders associated with Toll-Like Receptor 7 activity.

Claims (268)

1. A compound of Formula (I), or pharmaceutically acceptable salt thereof:

wherein:

R 1 is —NHR 6 or —NHCHR 6 R 9 ;

R 3 is -L 2 C(═O)OR 7 , —C(═O)OL 6 R 12 , —C(═O)OL 2 R 12 , -L 2 C(═O)OL 2 R 12 , -L 4 C(═O)OL 5 OH, -L 4 R 12 , -L 2 C(═O)OL 4 C(═O)L 2 R 12 , -L 2 C(═O)OL 6 R 12 , -L 2 C(═O)OL 4 C(═O)OL 2 R 12 , -L 2 C(═O)OL 4 C(═O)R 12 , -L 4 C(═O)OL 2 C(═O)R 12 , —CF 2 C(═O)R 7 , —CH═CHC(═O)OL 4 C(═O)R 12 , —OL 2 C(═O)OL 4 C(═O)R 12 , —OL 4 C(═O)OL 2 R 12 , —OL 4 C(═O)OL 2 C(═O)R 12 or -L 2 C(═O)OL 3 R 12 ;

R 4 is -L 2 C(═O)OR 7 , —C(═O)OL 6 R 12 , —C(═O)OL 2 R 12 , -L 2 C(═O)OL 2 R 12 , -L 4 C(═O)OL 5 OH, -L 4 R 12 , -L 2 C(═O)OL 4 C(═O)L 2 R 12 , -L 2 C(═O)OL 6 R 12 , -L 2 C(═O)OL 4 C(═O)OL 2 R 12 , -L 2 C(═O)OL 4 C(═O)R 12 , -L 4 C(═O)OL 2 C(═O)R 12 , —CF 2 C(═O)R 7 , —CH═CHC(═O)OL 4 C(═O)R 12 , —OL 2 C(═O)OL 4 C(═O)R 12 , —OL 4 C(═O)OL 2 R 12 , —OL 4 C(═O)OL 2 C(═O)R 12 or -L 2 C(═O)OL 3 R 12 ;

or R 4 is H, and R 3 is -L 2 C(═O)OR 7 , —C(═O)OL 6 R 12 , —C(═O)OL 2 R 12 , -L 2 C(═O)OL 2 R 12 , -L 4 C(═O)OL 5 OH, -L 4 R 12 , -L 2 C(═O)OL 4 C(═O)L 2 R 12 , -L 2 C(═O)OL 6 R 12 , -L 2 C(═O)OL 4 C(═O)OL 2 R 12 , -L 2 C(═O)OL 4 C(═O)R 12 , -L 4 C(═O)OL 2 C(═O)R 12 , —CF 2 C(═O)R 7 , —CF 2 C(═O)OR 7 , —N(R 11 ) 2 , —CH═CHC(═O)OL 4 C(═O)R 12 , —OL 2 C(═O)OL 4 C(═O)R 12 , —OL 4 C(═O)OL 2 R 12 , —OL 4 C(═O)OL 2 C(═O)R 12 or -L 2 C(═O)OL 3 R 12 ;

or R 3 is H, and R 4 is -L 2 C(═O)OR 7 , —C(═O)OL 6 R 12 , —C(═O)OL 2 R 12 , -L 2 C(═O)OL 2 R 12 , -L 4 C(═O)OL 5 OH, -L 4 R 12 , -L 2 C(═O)OL 4 C(═O)L 2 R 12 , -L 2 C(═O)OL 6 R 12 , -L 2 C(═O)OL 4 C(═O)OL 2 R 12 , -L 2 C(═O)OL 4 C(═O)R 12 , -L 4 C(═O)OL 2 C(═O)R 12 , —CF 2 C(═O)R 7 , —CF 2 C(═O)OR 7 , —N(R 11 ) 2 , —CH═CHC(═O)OL 4 C(═O)R 12 , —OL 2 C(═O)OL 4 C(═O)R 12 , —OL 4 C(═O)OL 2 R 12 , —OL 4 C(═O)OL 2 C(═O)R 12 or -L 2 C(═O)OL 3 R 12 ;

L 1 is —(CH 2 ) m —;

L 2 is —(CH 2 ) m —;

L 3 is —(CH 2 ) m —;

L 4 is —(CH 2 ) m —;

L 5 is —(CH 2 ) m —;

L 6 is —(CH 2 ) m O(CH 2 ) m —;

R 6 is —C 4 -C 6 alkyl;

R 7 is —C 1 -C 3 alkyl;

R 9 is L 1 OH;

each R 11 is independently selected from H or —C 1 -C 3 alkyl;

R 12 is

a) —N(R 11 ) 2 ;

b) an unsubstituted 5-6 membered heterocycloalkyl having 1 to 2 heteroatoms independently selected from N and O;

c) a 5-6 membered heterocycloalkyl having 1 to 2 heteroatoms independently selected from N and O substituted with ═O;

d) a 5-6 membered heterocycloalkyl having 1 to 2 heteroatoms independently selected from N and O substituted with C 1 -C 3 alkyl or —C(═O)OR 7 ;

e) an unsubstituted phenyl;

and

each m is independently selected from 1, 2, 3, and 4.

2. The compound of Formula (I) of claim 1 , or pharmaceutically acceptable salt thereof:

wherein:

R 1 is —NHR 6 or —NHCHR 6 R 9 ;

or R 4 is H, and R 3 is -L 2 C(═O)OR 7 , —C(═O)OL 6 R 12 , —C(═O)OL 2 R 12 , -L 2 C(═O)OL 2 R 12 , -L 4 C(═O)OL 5 OH, -L 4 R 12 , -L 2 C(═O)OL 4 C(═O)L 2 R 12 , -L 2 C(═O)OL 6 R 12 , -L 2 C(═O)OL 4 C(═O)OL 2 R 12 , -L 2 C(═O)OL 4 C(═O)R 12 , -L 4 C(═O)OL 2 C(═O)R 12 , —CF 2 C(═O)R 7 , —CH═CHC(═O)OL 4 C(═O)R 12 , —OL 2 C(═O)OL 5 C(═O)R 12 , —OL 4 C(═O)OL 2 R 12 , —OL 4 C(═O)OL 2 C(═O)R 12 or -L 2 C(═O)OL 3 R 12 ;

or R 3 is H, and R 4 is -L 2 C(═O)OR 7 , —C(═O)OL 6 R 12 , —C(═O)OL 2 R 12 , -L 2 C(═O)OL 2 R 12 , -L 4 C(═O)OL 5 OH, -L 4 R 12 , -L 2 C(═O)OL 4 C(═O)L 2 R 12 , -L 2 C(═O)OL 6 R 12 , -L 2 C(═O)OL 4 C(═O)OL 2 R 12 , -L 2 C(═O)OL 4 C(═O)R 12 , -L 4 C(═O)OL 2 C(═O)R 12 , —CF 2 C(═O)R 7 , —CH═CHC(═O)OL 4 C(═O)R 12 , —OL 2 C(═O)OL 4 C(═O)R 12 , —OL 4 C(═O)OL 2 R 12 , —OL 4 C(═O)OL 2 C(═O)R 12 or -L 2 C(═O)OL 3 R 12 ;

L 1 is —(CH 2 ) m —;

L 2 is —(CH 2 ) m —;

L 3 is —(CH 2 ) m —;

L 4 is —(CH 2 ) m —;

L 5 is —(CH 2 ) m —;

L 6 is —(CH 2 ) m O(CH 2 ) m —;

R 6 is —C 4 -C 6 alkyl;

R 7 is —C 1 -C 3 alkyl;

R 9 is L 1 OH;

each R 11 is independently selected from H or —C 1 -C 3 alkyl;

R 12 is

a) —N(R 11 ) 2 ;

b) an unsubstituted 5-6 membered heterocycloalkyl having 1 to 2 heteroatoms independently selected from N and O;

c) a 5-6 membered heterocycloalkyl having 1 to 2 heteroatoms independently selected from N and O substituted with ═O;

d) a 5-6 membered heterocycloalkyl having 1 to 2 heteroatoms independently selected from N and O substituted with C 1 -C 3 alkyl or —C(═O)OR 7 ;

e) an unsubstituted phenyl;

and

each m is independently selected from 1, 2, 3, and 4.

3. The compound of claim 1 , wherein the compound of Formula (I) is a compound of Formula (Ia) or Formula (Ib):

4. The compound of claim 1 , wherein,

R 1 is —NHR 6 or —NHCHR 6 R 9 ;

R 4 is —CF 2 C(═O)R 7 , -L 4 R 12 , —CH═CHC(═O)OL 4 C(═O)R 12 , —OL 2 C(═O)OL 4 C(═O)R 12 , —OL 4 C(═O)OL 2 R 12 , -L 2 C(═O)OR 7 , -L 2 C(═O)OL 4 C(═O)R 12 , —OL 4 C(═O)OL 2 C(═O)R 12 or -L 2 C(═O)OL 3 R 12 ;

or R 3 is H, and R 4 is —CF 2 C(═O)R 7 , -L 4 R 12 , —CH═CHC(═O)OL 4 C(═O)R 12 , —OL 2 C(═O)OL 4 C(═O)R 12 , —OL 4 C(═O)OL 2 R 12 , -L 2 C(═O)OR 7 , -L 2 C(═O)OL 4 C(═O)R 12 , —OL 4 C(═O)OL 2 C(═O)R 12 or -L 2 C(═O)OL 3 R 12 ;

L 1 is —CH 2 —;

L 2 is —CH 2 — or —CH 2 CH 2 —;

L 3 is —CH 2 CH 2 — or —CH 2 CH 2 CH 2 CH 2 —;

L 4 is —CH 2 —,

L 5 is —CH 2 CH 2 —,

L 6 is —(CH 2 ) 2 O(CH 2 ) 2 —;

R 6 is —C 4 alkyl or —C 5 alkyl;

R 7 is methyl, ethyl or propyl;

R 9 is LiOH;

each R 11 is independently selected from —C 1 -C 3 alkyl;

and

R 12 is

a) —N(R 11 ) 2 ;

b) an unsubstituted piperazinyl or an unsubstituted morpholinyl;

c) a 5-6 membered heterocycloalkyl having 1 to 2 heteroatoms independently selected from N and O substituted with ═O;

d) a piperazinyl substituted with C 1 -C 3 alkyl or —C(═O)OR 7 ;

an unsubstituted phenyl.

5. The compound of claim 1 , wherein,

R 1 is —NHR 6 or —NHCHR 6 R 9 ;

R 4 is H, and R 3 is -L 2 C(═O)OR 7 , —C(═O)OL 6 R 12 , —C(═O)OL 2 R 12 , -L 2 C(═O)OL 2 R 12 , -L 4 C(═O)OL 5 OH, -L 4 R 12 , -L 2 C(═O)OL 4 C(═O)L 2 R 12 , -L 2 C(═O)OL 6 R 12 , -L 2 C(═O)OL 4 C(═O)OL 2 R 12 , -L 2 C(═O)OL 4 C(═O)R 12 , -L 4 C(═O)OL 2 C(═O)R 12 , —CF 2 C(═O)OR 7 , —N(R 11 ) 2 or -L 2 C(═O)OL 3 R 12 ;

or R 3 is H, and R 4 is —CF 2 C(═O)R 7 , -L 4 R 12 , —CH═CHC(═O)OL 4 C(═O)R 12 , —OL 2 C(═O)OL 4 C(═O)R 12 , —OL 4 C(═O)OL 2 R 12 , -L 2 C(═O)OR 7 , -L 2 C(═O)OL 4 C(═O)R 12 , —OL 4 C(═O)OL 2 C(═O)R 12 , —CF 2 C(═O)OR 7 , —N(R 11 ) 2 or -L 2 C(═O)OL 3 R 12 ;

L 1 is —CH 2 —;

L 2 is —CH 2 — or —CH 2 CH 2 —:

L 3 is —CH 2 CH 2 — or —CH 2 CH 2 CH 2 CH 2 —;

L 4 is —CH 2 —,

L 5 is —CH 2 CH 2 —,

L 6 is —(CH 2 ) 2 O(CH 2 ) 2 —;

R 6 is —C 4 alkyl or —C 5 alkyl;

R 7 is methyl, ethyl or propyl;

R 9 is L 1 OH;

each R 11 is independently selected from —C 1 -C 3 alkyl;

and

R 12 is

a) —N(R 11 ) 2 ;

b) an unsubstituted piperazinyl or an unsubstituted morpholinyl;

c) a 5-6 membered heterocycloalkyl having 1 to 2 heteroatoms independently selected from N and O substituted with ═O;

d) a piperazinyl substituted with C 1 -C 3 alkyl or —C(═O)OR 7 ;

an unsubstituted phenyl.

6. The compound of claim 3 , wherein,

R 1 is —NHR 6 or —NHCHR 6 R 9 ;

R 3 is H, and R 4 is —CF 2 C(═O)R 7 , -L 4 R 12 , —CH═CHC(═O)OL 4 C(═O)R 12 , —OL 2 C(═O)OL 4 C(═O)R 12 , —OL 4 C(═O)OL 2 R 12 , -L 2 C(═O)OR 7 , -L 2 C(═O)OL 4 C(═O)R 12 , —OL 4 C(═O)OL 2 C(═O)R 12 or -L 2 C(═O)OL 3 R 12 ;

L 1 is —CH 2 —;

L 2 is —CH 2 — or —CH 2 CH 2 —;

L 3 is —CH 2 CH 2 — or —CH 2 CH 2 CH 2 CH 2 —;

L 4 is —CH 2 —,

L 5 is —CH 2 CH 2 —,

L 6 is —(CH 2 ) 2 O(CH 2 ) 2 —;

R 6 is —C 4 alkyl or —C 5 alkyl;

R 7 is methyl, ethyl or propyl;

R 9 is L 1 OH;

each R 11 is independently selected from —C 1 -C 3 alkyl;

and

R 12 is

a) —N(R 11 ) 2 ;

b) an unsubstituted piperazinyl or an unsubstituted morpholinyl;

c) a 5-6 membered heterocycloalkyl having 1 to 2 heteroatoms independently selected from N and O substituted with ═O;

d) a piperazinyl substituted with C 1 -C 3 alkyl or —C(═O)OR 7 ;

an unsubstituted phenyl.

7. The compound of claim 1 , wherein,

R 1 is —NHR 6 ;

R 3 is -L 2 C(═O)OL 4 C(═O)R 12 and R 4 is H;

or R 3 is H and R 4 is -L 2 C(═O)OL 4 C(═O)R 12 ;

R 6 is —C 4 -C 6 alkyl;

L 2 is —(CH 2 ) m —;

L 4 is —(CH 2 ) m —;

R 12 is an unsubstituted 5-6 membered heterocycloalkyl having 1 to 2 heteroatoms independently selected from N and O;

and

each m is independently selected from 1, 2, 3, and 4.

8. The compound of claim 1 , wherein,

R 1 is —NHR 6 ;

R 3 is -L 2 C(═O)OL 4 C(═O)L 2 R 12 and R 4 is H;

or R 3 is H and R 4 is -L 2 C(═O)OL 4 C(═O)L 2 R 12 ;

R 6 is —C 4 -C 6 alkyl;

L 2 is —(CH 2 ) m —;

L 4 is —(CH 2 ) m —;

R 12 is an unsubstituted 5-6 membered heterocycloalkyl having 1 to 2 heteroatoms independently selected from N and O;

and

each m is independently selected from 1, 2, 3, and 4.

9. The compound of claim 1 , wherein,

R 1 is —NHR 6 ;

R 3 is -L 2 C(═O)OL 4 C(═O)R 12 and R 4 is H;

or R 3 is H and R 4 is -L 2 C(═O)OL 4 C(═O)R 12 ;

R 6 is —C 5 alkyl;

L 2 is —CH 2 — or —CH 2 CH 2 —;

L 4 is —CH 2 —,

and

R 12 is an unsubstituted piperazinyl or an unsubstituted morpholinyl.

10. The compound of claim 1 , wherein,

R 1 is —NHR 6 ;

R 3 is -L 2 C(═O)OL 4 C(═O)L 2 R 12 and R 4 is H;

or R 3 is H and R 4 is -L 2 C(═O)OL 4 C(═O)L 2 R 12 ;

R 6 is —C 5 alkyl;

L 2 is —CH 2 — or —CH 2 CH 2 —;

L 4 is —CH 2 —,

and

R 12 is an unsubstituted piperazinyl or an unsubstituted morpholinyl.

11. The compound of claim 1 , wherein,

R 1 is —NHR 6 or —NHCHR 6 R 9 ;

R 3 is H and R 4 is -L 4 R 12 ;

or R 3 is -L 4 R 12 and R 4 is H;

L 1 is —(CH 2 ) m —;

L 4 is —(CH 2 ) m —;

R 6 is —C 4 -C 6 alkyl;

R 9 is L 1 OH;

R 12 is an unsubstituted 5-6 membered heterocycloalkyl having 1 to 2 heteroatoms independently selected from N and O;

and

each m is independently selected from 1, 2, 3, and 4.

12. The compound of claim 1 , wherein,

R 1 is —NHR 6 or —NHCHR 6 R 9 ;

R 3 is H and R 4 is -L 4 R 12 ;

or R 3 is -L 4 R 12 and R 4 is H;

L 1 is —(CH 2 )—;

L 4 is —(CH 2 )—;

R 6 is —C 4 alkyl or —C 5 alkyl;

R 9 is L 1 OH,

and

R 12 is an unsubstituted piperazinyl.

13. The compound of claim 1 , wherein the compound is selected from:

2-(dimethylamino)ethyl 4-((2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)methyl)-3-methoxybenzoate;

2-(2-(dimethylamino)ethoxy)ethyl 4-((2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)methyl)-3-methoxybenzoate;

methyl 2-(3-((2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)methyl)-4-methoxyphenyl)acetate;

ethyl 3-(3-((2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)methyl)-4-methoxyphenyl)propanoate;

methyl 2-(3-((2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)methyl)-4-methoxyphenyl)-2,2-difluoroacetate;

2-morpholino-2-oxoethyl 2-(3-((2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)methyl)-4-methoxyphenoxy)acetate;

2-morpholino-2-oxoethyl 2-(3-((2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)methyl)-4-methoxyphenyl)acetate;

2-morpholino-2-oxoethyl 2-(4-((2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)methyl)-3-methoxyphenyl)acetate;

2-(morpholin-4-yl)-2-oxoethyl 3-(4-{[2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]methyl}-3-methoxyphenyl)propanoate;

(S)-2-morpholino-2-oxoethyl 3-(3-((2-amino-4-((1-hydroxyhexan-2-yl)amino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)methyl)-4-methoxyphenyl)propanoate;

(S)-2-morpholino-2-oxoethyl 2-(4-((2-amino-4-((1-hydroxyhexan-2-yl)amino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)methyl)-3-methoxyphenyl)acetate;

(S)-2-morpholino-2-oxoethyl 2-(3-((2-amino-4-((I-hydroxyhexan-2-yl)amino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)methyl)-4-methoxyphenyl)acetate;

(S)-2-morpholino-2-oxoethyl 3-(4-((2-amino-4-((I-hydroxyhexan-2-yl)amino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)methyl)-3-methoxyphenyl)propanoate;

2-(morpholin-4-yl)-2-oxoethyl (2E)-3-(3-{[2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]methyl}-4-methoxyphenyl)prop-2-enoate;

2-(morpholin-4-yl)-2-oxoethyl 3-(3-{[2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]methyl}-4-methoxyphenyl)propanoate;

2-(benzyloxy)-2-oxoethyl 2-(4-{[2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]methyl}-3-methoxyphenyl)acetate;

2-(dipropylcarbamoyl)methyl 2-(4-{[2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]methyl}-3-methoxyphenyl)acetate:

2-(dimethylamino)-2-oxoethyl 2-(4-((2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)methyl)-3-methoxyphenyl)acetate;

2-(4-methylpiperazin-1-yl)ethyl 2-(4-{[2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]methyl}-3-methoxyphenyl)acetate;

2-hydroxyethyl 2-(4-{[2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]methyl}-3-methoxyphenyl)acetate;

4-(dimethylamino)butyl 2-(4-{[2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]methyl}-3-methoxyphenyl)acetate;

2-(morpholin-4-yl)ethyl 2-(4-{[2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]methyl}-3-methoxyphenyl)acetate;

2-(piperazin-1-yl)ethyl 2-(4-{[2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]methyl}-3-methoxyphenyl)acetate;

2-(dimethylamino)ethyl 2-(3-{[2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]methyl}-4-methoxyphenoxy)acetate:

2-(piperazin-1-yl)ethyl 2-(3-{[2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]methyl}-4-methoxyphenoxy)acetate:

2-(morpholin-4-yl)ethyl 2-(3-{[2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]methyl}-4-methoxyphenoxy)acetate;

2-(4-methylpiperazin-1-yl)ethyl 2-(3-{[2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]methyl}-4-methoxyphenoxy)acetate;

(S)-2-((2-amino-5-(2-methoxy-4-(piperazin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-d]pyrimidin-4-yl)amino)hexan-1-ol;

5-(2-methoxy-4-(piperazin-1-ylmethyl)benzyl)-N4-pentyl-5H-pyrrolo[3,2-d]pyrimidine-2,4-diamine;

5-(2-methoxy-5-(piperazin-1-ylmethyl)benzyl)-N4-pentyl-5H-pyrrolo[3,2-d]pyrimidine-2,4-diamine:

(S)-2-((2-amino-5-(2-methoxy-5-(piperazin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-d]pyrimidin-4-yl)amino)hexan-1-ol, and

5-(5-amino-2-methoxybenzyl)-N4-pentyl-5H-pyrrolo[3,2-d]pyrimidine-2,4-diamine.

14. The compound of claim 1 , wherein the compound is selected from:

2-morpholino-2-oxoethyl 2-(3-((2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)methyl)-4-methoxyphenoxy)acetate;

2-morpholino-2-oxoethyl 2-(3-((2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)methyl)-4-methoxyphenyl)acetate;

2-morpholino-2-oxoethyl 2-(4-((2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)methyl)-3-methoxyphenyl)acetate, and

2-(morpholin-4-yl)-2-oxoethyl 3-(4-{[2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]methyl}-3-methoxyphenyl)propanoate.

15. The compound of claim 1 , wherein the compound is selected from:

(S)-2-((2-amino-5-(2-methoxy-4-(piperazin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-d]pyrimidin-4-yl)amino)hexan-1-ol;

5-(2-methoxy-4-(piperazin-1-ylmethyl)benzyl)-N4-pentyl-5H-pyrrolo[3,2-d]pyrimidine-2,4-diamine;

5-(2-methoxy-5-(piperazin-1-ylmethyl)benzyl)-N4-pentyl-5H-pyrrolo[3,2-d]pyrimidine-2,4-diamine;

(S)-2-((2-amino-5-(2-methoxy-5-(piperazin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-d]pyrimidin-4-yl)amino)hexan-1-ol, and

5-(5-amino-2-methoxybenzyl)-N4-pentyl-5H-pyrrolo[3,2-d]pyrimidine-2,4-diamine.

16. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.

17. A method for treating a subject suffering from HIV, hepatitis B or hepatitis C, wherein the method comprises administering to the subject in need of such treatment an effective amount of a compound of claim 1 .

18. The pharmaceutical composition of claim 16 , wherein the compound is selected from: